Skip to main content

Galectin Therapeutics Inc ARS, filed Oct 13, 2026

Galectin Therapeutics Inc (GALT)

Galectin Therapeutics Inc. reported that belapectin 2mg/kg reduced esophageal varices by 49.3% in NAVIGATE’s per-protocol population (p-value<0.05) and by 68.1% among analyzed U.S. patients (p=0.02). AI summary

ARS 2026-10-13 For: 2025-12-31
View Original
Added on October 28, 2026